News Roche pays $1.7 billion for cancer specialist Ignyta Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta.
News After surging on lung cancer data, Ignyta looks to raise $16... San Diego based biotech firm Ignyta is capping off a week of success with a public stock offering t
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
